The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Davidson Michael H. since 2020.
This trader's CIK number is 1573785.
At the time of last reporting, Davidson Michael H. was the Chief Executive Officer of Newamsterdam Pharma Co N.v.. (stock ticker symbol NAMS).
Also see all insider trading activities at Newamsterdam Pharma Co N.v..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | TENX | 2,500 | $0 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | NAMS | 0 | $0 | 12,258 | $0 | 38,394 | $0 |
| 2024 | NAMS | 10,000 | $167,660 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | CLBS | 55,525 | $99,945 | 0 | $0 | 0 | $0 |
1. Tenax Therapeutics, Inc. (TENX)
2. Newamsterdam Pharma Co N.v. (NAMS)
3. Caladrius Biosciences, Inc. (CLBS)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-08-08 | TENX | Buy | 2,500 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-26 | NAMS | Sale | 12,258 | .00 | 0 |
| 2025-03-26 | NAMS | Option Ex | 38,394 | .00 | 0 |
| 2024-08-20 | NAMS | Buy | 5,000 | 16.27 | 81,350 |
| 2024-06-20 | NAMS | Buy | 5,000 | 17.26 | 86,310 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-09-09 | CLBS | Buy | 55,525 | 1.80 | 99,945 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Davidson Michael H. (Chief Executive Officer of Newamsterdam Pharma Co N.v. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.